mRNA and Lipid Nanoparticles (LNPs): Formation, Delivery Mechanism, Microfluidic Mixing & Therapeutic Applications

 

Table of Content

• What is mRNA
• Why naked mRNA is unstable
• What lipids are used in mRNA delievery system
• How microfluidic mixing works
• How LNPs deliver cargo into cells
• Applications in vaccines and therapeutics
• References

What is mRNA?

• Messenger ribonucleic acid (mRNA) is the “disposable copy” of a gene that carries genetic information from DNA to ribosomes, where it serves as a template for protein synthesis.
• It is a linear chain of ribonucleotides that can range from a few hundred to hundreds of thousands of nucleotides in length.
• A typical eukaryotic mRNA structure has: a 5′ untranslated region (5′‑UTR), a protein‑coding open reading frame, a 3′‑UTR, plus regulatory elements at both ends.
• The 5′ end is usually modified with a 7‑methylguanosine “cap” linked via a special 5′–5′ triphosphate; this cap protects mRNA from degradation, helps splicing and nuclear export, and is essential for cap‑dependent translation initiation.
• The 3′ end typically carries a poly(A) tail (dozens to ~250 adenines) that contributes to mRNA stability, translation efficiency, and lifespan in the cell.
• mRNA is not just a linear code: it folds into complex secondary and tertiary structures that can regulate almost every step of its life cycle, including translation initiation, elongation, termination, localization, and degradation.
• mRNA modifications (such as N6‑methyladenosine and others) and chemical changes at its ends add an extra regulatory layer (“epitranscriptome”) affecting stability, translation, and immune recognition.
• In cells, mRNA is packaged with proteins into messenger ribonucleoprotein particles (mRNPs) that control its export from the nucleus, localization, translation, and decay.
• Synthetic mRNAs can be produced in vitro and, with optimized caps, tails, and nucleoside modifications, are used as therapeutic agents and vaccines.

Why naked mRNA is unstable

• Prone to nuclease attack: Naked mRNA in blood and other biofluids is rapidly degraded by abundant extracellular ribonucleases (RNases); ribonuclease activity is specifically cited as a key reason naked extracellular RNA is highly unstable.
• Single-stranded and exposed backbone: mRNA’s largely single-stranded structure leaves its 3′–5′ phosphodiester bonds exposed, making them susceptible to enzyme-mediated cleavage and chemical hydrolysis, unlike more structured RNAs or circRNAs that better resist nucleases.
• Intrinsic chemical instability (self-hydrolysis): The RNA backbone undergoes base‑catalyzed transesterification (hydrolysis), producing chain breaks; this is accelerated by higher temperature and alkaline pH, setting a fundamental limit on naked mRNA stability in solution.
• Temperature sensitivity: Increases in temperature sharply accelerate hydrolysis and degradation; naked mRNA shows faster decay at 35–50 °C, and storage conditions critically affect its half‑life.
• Lack of protective carriers: Without encapsulation in lipid nanoparticles or association with proteins, mRNA remains directly exposed to RNases and reactive species; LNPs or other carriers can slow degradation by several‑fold compared with naked mRNA.
• Rapid clearance in vivo: Naked RNA (including siRNA/mRNA) has a very short plasma half‑life and is rapidly cleared (e.g., by the kidney), limiting the time it remains intact and functional in circulation.
• Immune recognition–linked decay: Unmodified naked mRNA is sensed as foreign, activating innate immune pathways and RNases that further promote its degradation, contributing to poor persistence in biological environments.

What lipids are used in mRNA delievery system

• Core LNP lipids (standard 4‑component systems)
• Ionizable cationic lipids (e.g., DLin‑MC3‑DMA, ALC‑0315, SM‑102, TT3, many new ionizable lipids).
• Helper phospholipids / neutral lipids: DSPC (1,2‑distearoyl‑sn‑glycero‑3‑phosphocholine), DOPE (1,2‑dioleoyl‑sn‑glycerol‑3‑phosphoethanolamine), PC, PE, PS and related phospholipids.
• Cholesterol (and cholesterol‑based helper or ionizable lipids).
• PEG‑lipids / PEGylated lipids (lipid‑anchored polyethylene glycol such as ALC‑0159, PEG2000‑DMG/DMG‑PEG2k, DMG‑PEG5k and other PEG‑phosphoethanolamine, PEG‑cholesterol, PEG‑ceramide lipids).
• Alternative or modified helper lipids
• Neutral lipids: DOPC, sphingomyelin, ceramide.
• Anionic lipids: phosphatidylserine (PS), phosphatidylglycerol, phosphatidic acid
• Cationic helper lipids: DOTAP, ethyl phosphatidylcholine.
• Sterol variants and bile‑acid helpers
• Ionizable sterol lipids (e.g., CS22021) used as the main ionizable component in 3‑component LNPs.
• Bile acids as cholesterol analogs in “BA‑LNPs”: cholic acid, chenodeoxycholic acid, deoxycholic acid, lithocholic acid (often replacing cholesterol).
• Representative named ionizable / helper lipids mentioned
• ALC‑0315 (ionizable), ALC‑0159 (PEG‑lipid), DLin‑MC3‑DMA, SM‑102, C12‑200, cKK‑E12, 98N12‑5, BAME‑O16B, 306Oi10, TT3, DC‑cholesterol, BHEM‑cholesterol, various new amino ionizable lipids (e.g., Lipid 16, 23, 119‑23).

How microfluidic mixing works

• In microfluidic channels, flows are usually laminar (low Reynolds number), so mixing is not by turbulence but mainly by slow molecular diffusion across the interface of side‑by‑side streams.
• Diffusive mixing: molecules move from high to low concentration; mixing time scales with the square of diffusion distance, so thick, unmixed layers mix very slowly.
• Hydrodynamic focusing / lamination squeezes one stream into a very thin layer between others, shortening diffusion distance and giving much faster diffusion‑based mixing.
• Chaotic advection in passive mixers: channel geometries (serpentine, obstacles, herringbone, split‑and‑recombine, sinusoidal, 3D structures) repeatedly stretch, fold, and reorient fluid layers, increasing interface area and accelerating diffusion‑driven mixing.
• In droplet (plug) microfluidics, internal recirculation vortices, twirling during droplet formation, and Dean vortices in curved/serpentine sections stir the droplet, creating strong convective mixing inside each droplet.
• Boundary-condition engineering (e.g., patterned hydrophobic “slip” spots, surface roughness, baffles) induces secondary flows, stretching/folding and local recirculation even in straight channels, giving passive chaotic mixing at low Re.
• Active mixers add external energy (acoustic/surface acoustic waves, electric fields, magnetic/pressure/thermal actuation) to drive time‑dependent flows and vortices, producing chaotic advection and much faster mixing than diffusion alone.
• Overall, microfluidic mixing works by combining geometry or external forcing to create advection (stretching, folding, vortices) that increases contact area, while diffusion at these enlarged interfaces completes mixing.

How LNPs deliver cargo into cells

Serum protein binding and targeting

• In blood, LNPs rapidly bind proteins such as ApoE, which then interact with LDL receptors on cells to promote uptake, especially in hepatocytes.

Cellular uptake (endocytosis)

• LNPs enter cells mainly by endocytosis, including clathrin‑mediated endocytosis and macropinocytosis; phagocytosis and caveolae‑mediated routes can also contribute.
• Entry route depends on size, charge, shape, and rigidity of the LNPs.

Trafficking in endosomal–lysosomal system

• Internalized LNPs are first in early endosomes, then can traffic to recycling endosomes, late endosomes, and finally lysosomes.
• Many LNPs are degraded or recycled; only a small fraction reach “productive” compartments that allow escape.

pH‑triggered lipid activation

• As endosomes acidify, ionizable lipids become protonated, destabilizing the LNP and promoting interaction with the negatively charged endosomal membrane.

Membrane fusion / disruption and escape

• Protonated ionizable lipids and certain topologies (nonlamellar, cubic, “structurally active” lipids) lower the energy for fusion or disruption of endosomal membranes, enabling RNA to cross into cytosol.
• Proposed mechanisms include lamellar‑to‑inverted hexagonal transition, pH‑sensitive amphiphilic disruption, and vesicle budding‑and‑collapse (VBC); all aim to create transient defects that let nucleic acids out.

Efficiency and final cytosolic release

• Endosomal escape is very inefficient: typically ~1–3% (often <10%) of internalized RNA reaches the cytosol.
• After escape, RNA may reside in lipid/RNA aggregates whose slow dissolution can further limit functional delivery.

Applications in vaccines and therapeutics

Infectious disease vaccines (prophylactic mRNA vaccines)

• LNP‑mRNA vaccines are clinically used against COVID‑19 and are being developed for other infectious diseases (influenza, RSV, viral lung infections).
• LNPs protect mRNA, improve cellular uptake and endosomal escape, and can act as adjuvants enhancing antibody and T‑cell responses.

Cancer vaccines and tumor immunotherapy

• LNP‑formulated mRNA cancer vaccines encode tumor antigens or neoantigens to stimulate cytotoxic T cells and anti‑tumor immunity.
• LNPs enable targeted, controlled‑release mRNA vaccines for tumor immunity and combination with other immunotherapies.

Genetic and rare disease therapies (protein replacement / gene silencing / editing)

• LNPs deliver siRNA therapeutics such as patisiran (Onpattro) for hereditary transthyretin amyloidosis.
• LNP‑mRNA systems are used for protein replacement (e.g., factor VIII/IX in hemophilia models) and for delivering genome‑editing components (CRISPR) in preclinical studies.

Broader RNA therapeutics and systemically delivered drugs

• LNPs carry diverse RNA cargoes (mRNA, siRNA, miRNA) to treat genetic diseases, cancers, and infectious diseases in preclinical and clinical pipelines.
• They are used for cytotoxic chemotherapy, antibiotics, and other small‑molecule drugs, improving pharmacokinetics and reducing toxicity.

Other emerging applications

• LNPs are explored for medical imaging, cosmetics, nutrition, and agrochemical delivery because of their versatility and tunable composition.
• New ionizable lipids (e.g., Lipid 10) support both systemic siRNA/mRNA therapy and intramuscular vaccine delivery with strong efficacy and tolerability.

References

• Albertsen, C., Kulkarni, J., Witzigmann, D., Lind, M., Petersson, K., & Simonsen, J. (2022). The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Advanced Drug Delivery Reviews, 188, 114416. https://doi.org/10.1016/j.addr.2022.114416
• Aldosari, B., Alfagih, I., & Almurshedi, A. (2021). Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics, 13. https://doi.org/10.3390/pharmaceutics13020206
• Aliakbarinodehi, N., Niederkofler, S., Emilsson, G., Parkkila, P., Olsén, E., Jing, Y., Sjöberg, M., Agnarsson, B., Lindfors, L., & Höök, F. (2024). Time-Resolved Inspection of Ionizable Lipid-Facilitated Lipid Nanoparticle Disintegration and Cargo Release at an Early Endosomal Membrane Mimic. ACS Nano, 18, 22989–23000. https://doi.org/10.1021/acsnano.4c04519
• Asr, M., Dayani, F., Segherloo, F., Kamedi, A., Neill, A., Macloughlin, R., & Doroudian, M. (2023). Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections. Pharmaceutics, 15. https://doi.org/10.3390/pharmaceutics15041127
• Barros, C., Alfaro, M., Csiki-Fejer, A., Bhatnagar, B., Tschessalov, S., Ferguson, S., Barua, S., Darvari, R., & Topp, E. (2025). Comparative Analysis of mRNA Degradation Kinetics Using Chromatographic and Electrophoretic Methods. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c01543
• Barzoki, A. (2023). Enhanced mixing efficiency and reduced droplet size with novel droplet generators. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-55514-7
• Barzoki, A., Mohseni, A., Bazyar, M., & Mohammadi, K. (2024). Comparative Experimental and Numerical Study of Mixing Efficiency in 3D-Printed Microfluidic Droplet Generators: T Junction, Cross Junction, and Asymmetric Junctions with Varying Angles. Chemical Engineering and Processing - Process Intensification. https://doi.org/10.1016/j.cep.2024.110002
• Blenke, E., Örnskov, E., Schöneich, C., Nilsson, G., Volkin, D., Mastrobattista, E., Almarsson, Ö., & Crommelin, D. (2022). The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case. Journal of Pharmaceutical Sciences, 112, 386–403. https://doi.org/10.1016/j.xphs.2022.11.001
• Bringer, M., Gerdts, C., Song, H., Tice, J., & Ismagilov, R. (2004). Microfluidic systems for chemical kinetics that rely on chaotic mixing in droplets. Philosophical Transactions of the Royal Society of London. Series A: Mathematical, Physical and Engineering Sciences, 362, 1087–1104. https://doi.org/10.1098/rsta.2003.1364
• Buschmann, M., Carrasco, M., Alishetty, S., Paige, M., Alameh, M., & Weissman, D. (2021). Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines, 9. https://doi.org/10.3390/vaccines9010065
• Cai, S., Jin, Y., Lin, Y., He, Y., Zhang, P., Ge, Z., & Yang, W. (2023). Micromixing within microfluidic devices: Fundamentals, design, and fabrication. Biomicrofluidics, 17(6), 061503. https://doi.org/10.1063/5.0178396
• Capretto, L., Cheng, W., Hill, M., & Zhang, X. (2011). Micromixing within microfluidic devices. Topics in Current Chemistry, 304, 27–68. https://doi.org/10.1007/128_2011_150
• Castellano, M., Blanco, V., Calzi, M., Costa, B., Witwer, K., Hill, M., Cayota, A., Segovia, M., & Tosar, J. (2024). Ribonuclease activity undermines immune sensing of naked extracellular RNA. bioRxiv. https://doi.org/10.1101/2024.04.23.590771
• Castellano, M., Blanco, V., Calzi, M., Costa, B., Witwer, K., Hill, M., Cayota, A., Segovia, M., & Tosar, J. (2025). Ribonuclease activity undermines immune sensing of naked extracellular RNA. Cell Genomics, 5. https://doi.org/10.1016/j.xgen.2025.100874
• Chatterjee, S., Kon, E., Sharma, P., & Peer, D. (2024). Endosomal escape: A bottleneck for LNP-mediated therapeutics. Proceedings of the National Academy of Sciences, 121. https://doi.org/10.1073/pnas.2307800120
• Cheng, Y., Zhao, E., Yang, X., Luo, C., Zi, G., Wang, R., Xu, Y., & Peng, B. (2024). Entrapment of lipid nanoparticles in peripheral endosomes but not lysosomes impairs intracellular trafficking and endosomal escape. International Journal of Pharmaceutics, 125024. https://doi.org/10.1016/j.ijpharm.2024.125024
• Chiaruttini, C., & Guillier, M. (2019). On the role of mRNA secondary structure in bacterial translation. Wiley Interdisciplinary Reviews: RNA, 11. https://doi.org/10.1002/wrna.1579
• Cullis, P., & Felgner, P. (2024). The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nature Reviews Drug Discovery, 23, 709–722. https://doi.org/10.1038/s41573-024-00977-6
• Del Campo, C., Bartholomäus, A., Fedyunin, I., & Ignatova, Z. (2015). Secondary Structure across the Bacterial Transcriptome Reveals Versatile Roles in mRNA Regulation and Function. PLoS Genetics, 11. https://doi.org/10.1371/journal.pgen.1005613
• Douroum, E., Laouedj, S., Kouadri, A., Naas, T., Khelladi, S., & Benazza, A. (2021). High hydrodynamic and thermal mixing performances of efficient chaotic micromixers: A comparative study. Chemical Engineering and Processing - Process Intensification. https://doi.org/10.1016/j.cep.2021.108394
• Eygeris, Y., Gupta, M., Kim, J., & Sahay, G. (2021). Chemistry of Lipid Nanoparticles for RNA Delivery. Accounts of Chemical Research. https://doi.org/10.1021/acs.accounts.1c00544
• Fan, J., Li, S., Wu, Z., & Chen, Z. (2018). Diffusion and mixing in microfluidic devices. Microfluidics for Pharmaceutical Applications. https://doi.org/10.1016/b978-0-12-812659-2.00003-x
• Faraway, R., Zenklusen, D., & Plaschka, C. (2025). Mechanisms of Messenger RNA Packaging and Export. Annual Review of Cell and Developmental Biology, 41(1), 479–504. https://doi.org/10.1146/annurev-cellbio-101123-045256
• Frye, M., Harada, B., Behm, M., & He, C. (2018). RNA modifications modulate gene expression during development. Science, 361, 1346–1349. https://doi.org/10.1126/science.aau1646
• Gao, S., Dagnaes-Hansen, F., Nielsen, E., Wengel, J., Besenbacher, F., Howard, K., & Kjems, J. (2009). The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Molecular Therapy, 17(7), 1225–1233. https://doi.org/10.1038/mt.2009.91
• Gilbert, W., Bell, T., & Schaening, C. (2016). Messenger RNA modifications: Form, distribution, and function. Science, 352, 1408–1412. https://doi.org/10.1126/science.aad8711
• Gilleron, J., et al. (2013). Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape. Nature Biotechnology, 31, 638–646. https://doi.org/10.1038/nbt.2612
• Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 6, 1078–1094. https://doi.org/10.1038/s41578-021-00358-0
• Jahangirifard, S., Salomon, R., & Bazaz, S. (2024). Deformable baffles coupled with pulsatile flow improve mixing in microfluidic devices. Chemical Engineering Research and Design. https://doi.org/10.1016/j.cherd.2024.07.015
• Jiao, X., et al. (2024). Insights into the formulation of lipid nanoparticles for the optimization of mRNA therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 16(5), e1992. https://doi.org/10.1002/wnan.1992
• Johansson, J., et al. (2024). Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol. Nature Communications, 16. https://doi.org/10.1038/s41467-025-60959-z
• Jung, H., Lee, S., Lee, S., Youn, H., & Im, H. (2022). Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging. Theranostics, 12, 7509–7531. https://doi.org/10.7150/thno.77259
• Lam, K., et al. (2023). Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipid‐Nanoparticle Components for Therapeutic and Vaccine Applications. Advanced Materials, 35. https://doi.org/10.1002/adma.202209624
• Lambris, J., Oeffinger, M., & Zenklusen, D. (2019). The Biology of mRNA: Structure and Function. Springer. https://doi.org/10.1007/978-3-030-31434-7
• Lee, C., Wang, W., Liu, C., & Fu, L. (2016). Passive mixers in microfluidic systems: A review. Chemical Engineering Journal, 288, 146–160. https://doi.org/10.1016/j.cej.2015.10.122
• Lee, Y., Choe, J., Park, O., & Kim, Y. (2020). Molecular Mechanisms Driving mRNA Degradation by m6A Modification. Trends in Genetics, 36(3), 178–188. https://doi.org/10.1016/j.tig.2019.12.007
• Li, B., et al. (2024). Accelerating ionizable lipid discovery for mRNA delivery using machine learning and combinatorial chemistry. Nature Materials, 23, 1002–1008. https://doi.org/10.1038/s41563-024-01867-3
• Li, X., et al. (2025). Design Strategies for Novel Lipid Nanoparticle for mRNA Vaccine and Therapeutics: Current Understandings and Future Perspectives. MedComm, 6. https://doi.org/10.1002/mco2.70414
• Liu, H., Chen, M., Payne, T., Porter, C., Pouton, C., & Johnston, A. (2024). Beyond the Endosomal Bottleneck: Understanding the Efficiency of mRNA/LNP Delivery. Advanced Functional Materials, 34. https://doi.org/10.1002/adfm.202404510
• Liu, L., et al. (2025). PEGylated lipid screening, composition optimization, and structure-activity relationship determination for lipid nanoparticle-mediated mRNA delivery. Nanoscale. https://doi.org/10.1039/d5nr00433k
• LoPresti, S., Arral, M., Chaudhary, N., & Whitehead, K. (2022). The replacement of helper lipids with charged alternatives in lipid nanoparticles facilities targeted mRNA delivery to the spleen and lungs. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2022.03.046
• Lu, Z., & Sun, D. (2025). Mechanism of pH-sensitive Amphiphilic Endosomal Escape of Ionizable Lipid Nanoparticles for Cytosolic Nucleic Acid Delivery. Pharmaceutical Research, 42, 1065–1077. https://doi.org/10.1007/s11095-025-03890-8
• Maeki, M., Uno, S., Niwa, A., Okada, Y., & Tokeshi, M. (2022). Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery. Journal of Controlled Release, 344, 80–96. https://doi.org/10.1016/j.jconrel.2022.02.017
• Mauger, D., Siegfried, N., & Weeks, K. (2013). The genetic code as expressed through relationships between mRNA structure and protein function. FEBS Letters, 587, 1180–1188. https://doi.org/10.1016/j.febslet.2013.03.002
• Mustoe, A., et al. (2018a). Pervasive Regulatory Functions of mRNA Structure Revealed by High-Resolution SHAPE Probing. Cell, 173(1), 181–195.e18. https://doi.org/10.1016/j.cell.2018.02.034
• Mustoe, A., Corley, M., Laederach, A., & Weeks, K. (2018b). Messenger RNA Structure Regulates Translation Initiation: A Mechanism Exploited from Bacteria to Humans. Biochemistry, 57(26), 3537–3539. https://doi.org/10.1021/acs.biochem.8b00395
• Naidu, G., et al. (2023). A Combinatorial Library of Lipid Nanoparticles for Cell Type‐Specific mRNA Delivery. Advanced Science, 10. https://doi.org/10.1002/advs.202301929
• Ouro-Koura, H., et al. (2021). Boundary Condition Induced Passive Chaotic Mixing in Straight Microchannels. Physics of Fluids. https://doi.org/10.1063/5.0088014
• Paroor, S., et al. (2025). Lipid Nanoparticles for the Delivery of mRNA. Methods in Molecular Biology, 2965, 341–354. https://doi.org/10.1007/978-1-0716-4742-4_16
• Patel, S., et al. (2020). Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nature Communications, 11. https://doi.org/10.1038/s41467-020-14527-2
• Patel, S., et al. (2024). Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery. Theranostics, 14, 1–16. https://doi.org/10.7150/thno.89913
• Pei, D. (2025). Endosomal Escape of Lipid Nanoparticles: A Perspective on the Literature Data. ACS Nano. https://doi.org/10.1021/acsnano.5c11721
• Qiu, Y., et al. (2025). Investigation of Efficient Mixing Enhancement in a Droplet Micromixer with Short Mixing Length at Low Reynolds Number. Micromachines, 16. https://doi.org/10.3390/mi16060715
• Ramanathan, A., Robb, G., & Chan, S. (2016). mRNA capping: biological functions and applications. Nucleic Acids Research, 44, 7511–7526. https://doi.org/10.1093/nar/gkw551
• Reichmuth, A., Oberli, M., Jaklenec, A., Langer, R., & Blankschtein, D. (2016). mRNA vaccine delivery using lipid nanoparticles. Therapeutic Delivery, 7(5), 319–334. https://doi.org/10.4155/tde-2016-0006
• Ribovski, L., Joshi, B., Gao, J., & Zuhorn, I. (2023). Breaking free: endocytosis and endosomal escape of extracellular vesicles. Extracellular Vesicles and Circulating Nucleic Acids, 4, 283–305. https://doi.org/10.20517/evcna.2023.26
• Rigby, R., & Rehwinkel, J. (2015). RNA degradation in antiviral immunity and autoimmunity. Trends in Immunology, 36, 179–188. https://doi.org/10.1016/j.it.2015.02.001
• Sajid, M., Moazzam, M., Kato, S., Cho, K., & Tiwari, R. (2020). Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside. Pharmaceuticals, 13. https://doi.org/10.3390/ph13100294
• Saw, P., & Song, E. (2024). Advancements in clinical RNA therapeutics: Present developments and prospective outlooks. Cell Reports Medicine, 5. https://doi.org/10.1016/j.xcrm.2024.101555
• Schlich, M., et al. (2020). Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioengineering & Translational Medicine, 6. https://doi.org/10.1002/btm2.10213
• Spadea, A., et al. (2022). Nucleic Acid-Loaded Lipid Nanoparticle Interactions with Model Endosomal Membranes. ACS Applied Materials & Interfaces, 14, 30371–30384. https://doi.org/10.1021/acsami.2c06065
• Su, K., et al. (2024). Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation. Nature Communications, 15. https://doi.org/10.1038/s41467-024-50093-7
• Suh, Y., & Kang, S. (2010). A Review on Mixing in Microfluidics. Micromachines, 1, 82–111. https://doi.org/10.3390/mi1030082
• Sun, D., & Lu, Z. (2023). Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Delivery. Pharmaceutical Research, 40, 27–46. https://doi.org/10.1007/s11095-022-03460-2
• Swetha, K., et al. (2023). Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines. Vaccines, 11. https://doi.org/10.3390/vaccines11030658
• Szomor, Z., Gyimah, N., Fürjes, P., & Pardy, T. (2024). 3D Finite Element Modelling of Mixing Phenomena in Droplet-based Microfluidic Systems. BEC 2024, 1–4. https://doi.org/10.1109/bec61458.2024.10737975
• Szomor, Z., Gyimah, N., Pardy, T., & Fürjes, P. (2025). Three-dimensional finite element modelling of chemical environment in droplet-based microfluidic systems for drug therapy applications. Physics of Fluids. https://doi.org/10.1063/5.0275809
• Tenchov, R., Bird, R., Curtze, A., & Zhou, Q. (2021). Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. https://doi.org/10.1021/acsnano.1c04996
• Tosar, J., et al. (2020). Fragmentation of extracellular ribosomes and tRNAs shapes the extracellular RNAome. Nucleic Acids Research, 48, 12874–12888. https://doi.org/10.1093/nar/gkaa674
• Uchida, S., Perche, F., Pichon, C., & Cabral, H. (2020). Nanomedicine-based approaches for mRNA delivery. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.0c00618
• Vasileva, O., et al. (2024). Composition of lipid nanoparticles for targeted delivery: application to mRNA therapeutics. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1466337
• Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020). Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics, 12. https://doi.org/10.3390/pharmaceutics12020102
• Wang, C., & Liu, H. (2021). Factors influencing degradation kinetics of mRNAs and half-lives of microRNAs, circRNAs, lncRNAs in blood in vitro using quantitative PCR. Scientific Reports, 12. https://doi.org/10.1038/s41598-022-11339-w
• Wang, C., Zhang, Y., & Dong, Y. (2021). Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications. Accounts of Chemical Research. https://doi.org/10.1021/acs.accounts.1c00550
• Wang, J., et al. (2015a). Fluid mixing in droplet-based microfluidics with a serpentine microchannel. RSC Advances, 5, 104138–104144. https://doi.org/10.1039/c5ra21181f
• Wang, J., et al. (2024). Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines, 12. https://doi.org/10.3390/vaccines12101148
• Wang, J., et al. (2025). Endo/Lysosomal-Escapable Lipid Nanoparticle Platforms for Enhancing mRNA Delivery in Cancer Therapy. Pharmaceutics, 17. https://doi.org/10.3390/pharmaceutics17070803
• Wang, Z., et al. (2025). Ionizable Sterol Lipid-Based Three-Component Lipid Nanoparticles for Localized Delivery of mRNA Vaccine with Stronger Cellular Immune Responses. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c04597
• Warmiński, M., et al. (2023). Chemical Modifications of mRNA Ends for Therapeutic Applications. Accounts of Chemical Research, 56, 2814–2826. https://doi.org/10.1021/acs.accounts.3c00442
• Wayment-Steele, H., et al. (2020). Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Research, 49, 10604–10617. https://doi.org/10.1093/nar/gkab764
• Wu, L., et al. (2024). Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines, 12. https://doi.org/10.3390/vaccines12020186
• Wu, S., Lin, L., Shi, L., & Liu, S. (2024). An overview of lipid constituents in lipid nanoparticle mRNA delivery systems. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 16(4), e1978. https://doi.org/10.1002/wnan.1978
• Wu, X., & Bartel, D. (2017). Widespread Influence of 3′-End Structures on Mammalian mRNA Processing and Stability. Cell, 169, 905–917.e11. https://doi.org/10.1016/j.cell.2017.04.036
• Wu, Y., Yu, S., & De Lázaro, I. (2024). Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines. Nanoscale. https://doi.org/10.1039/d4nr00019f
• Xu, Y., et al. (2023). Rational design and combinatorial chemistry of ionizable lipids for RNA delivery. Journal of Materials Chemistry B. https://doi.org/10.1039/d3tb00649b
• Yang, L., et al. (2018). Fluid mixing in droplet‐based microfluidics with T junction and convergent–divergent sinusoidal microchannels. Electrophoresis, 39. https://doi.org/10.1002/elps.201700374
• Yang, L., et al. (2022). Recent Advances in Lipid Nanoparticles for Delivery of mRNA. Pharmaceutics, 14. https://doi.org/10.3390/pharmaceutics14122682
• Yu, Q., Chen, X., Li, X., & Zhang, D. (2022). Optimized design of droplet micro-mixer with sinusoidal structure based on Pareto genetic algorithm. International Communications in Heat and Mass Transfer. https://doi.org/10.1016/j.icheatmasstransfer.2022.106124
• Yuan, S., et al. (2021). An Investigation of Flow Patterns and Mixing Characteristics in a Cross-Shaped Micromixer within the Laminar Regime. Micromachines, 12. https://doi.org/10.3390/mi12040462
• Zaidi, S., et al. (2023). Engineering siRNA therapeutics: challenges and strategies. Journal of Nanobiotechnology, 21. https://doi.org/10.1186/s12951-023-02147-z
• Zhang, Y., Sun, C., Wang, C., Jankovic, K., & Dong, Y. (2021). Lipids and Lipid Derivatives for RNA Delivery. Chemical Reviews. https://doi.org/10.1021/acs.chemrev.1c00244
• Zheng, L., Bandara, S., & Leal, C. (2022). Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm. Proceedings of the National Academy of Sciences. https://doi.org/10.1101/2022.05.20.492895